Press release
March 26, 2026
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
NovoCure Ltd (NVCR)
BAAR, Switzerland --(BUSINESS WIRE)--Mar. 26, 2026-- Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line